1
|
De Castro F, Stefàno E, Fanizzi FP, Di Corato R, Abdalla P, Luchetti F, Nasoni MG, Rinaldi R, Magnani M, Benedetti M, Antonelli A. Compatibility of Nucleobases Containing Pt(II) Complexes with Red Blood Cells for Possible Drug Delivery Applications. Molecules 2023; 28:6760. [PMID: 37836603 PMCID: PMC10574024 DOI: 10.3390/molecules28196760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 09/19/2023] [Accepted: 09/20/2023] [Indexed: 10/15/2023] Open
Abstract
The therapeutic advantages of some platinum complexes as major anticancer chemotherapeutic agents and of nucleoside analogue-based compounds as essential antiviral/antitumor drugs are widely recognized. Red blood cells (RBCs) offer a potential new strategy for the targeted release of therapeutic agents due to their biocompatibility, which can protect loaded drugs from inactivation in the blood, thus improving biodistribution. In this study, we evaluated the feasibility of loading model nucleobase-containing Pt(II) complexes into human RBCs that were highly stabilized by four N-donors and susceptible to further modification for possible antitumor/antiviral applications. Specifically, platinum-based nucleoside derivatives [PtII(dien)(N7-Guo)]2+, [PtII(dien)(N7-dGuo)]2+, and [PtII(dien)(N7-dGTP)] (dien = diethylenetriamine; Guo = guanosine; dGuo = 2'-deoxy-guanosine; dGTP = 5'-(2'-deoxy)-guanosine-triphosphate) were investigated. These Pt(II) complexes were demonstrated to be stable species suitable for incorporation into RBCs. This result opens avenues for the possible incorporation of other metalated nucleobases analogues, with potential antitumor and/or antiviral activity, into RBCs.
Collapse
Affiliation(s)
- Federica De Castro
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Via Monteroni, 73100 Lecce, Italy; (F.D.C.); (E.S.)
| | - Erika Stefàno
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Via Monteroni, 73100 Lecce, Italy; (F.D.C.); (E.S.)
| | - Francesco Paolo Fanizzi
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Via Monteroni, 73100 Lecce, Italy; (F.D.C.); (E.S.)
| | - Riccardo Di Corato
- Center for Biomolecular Nanotechnologies, Istituto Italiano di Tecnologia, 73010 Arnesano, Italy;
- Institute for Microelectronics and Microsystems (IMM), CNR, Via Monteroni, 73100 Lecce, Italy;
| | - Pasant Abdalla
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Via Saffi 2, 61029 Urbino, Italy; (P.A.); (F.L.); (M.G.N.); (M.M.)
| | - Francesca Luchetti
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Via Saffi 2, 61029 Urbino, Italy; (P.A.); (F.L.); (M.G.N.); (M.M.)
| | - Maria Gemma Nasoni
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Via Saffi 2, 61029 Urbino, Italy; (P.A.); (F.L.); (M.G.N.); (M.M.)
| | - Rosaria Rinaldi
- Institute for Microelectronics and Microsystems (IMM), CNR, Via Monteroni, 73100 Lecce, Italy;
- Mathematics and Physics “E. De Giorgi” Department, University of Salento, Via Monteroni, 73100 Lecce, Italy
| | - Mauro Magnani
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Via Saffi 2, 61029 Urbino, Italy; (P.A.); (F.L.); (M.G.N.); (M.M.)
| | - Michele Benedetti
- Department of Biological and Environmental Sciences and Technologies, University of Salento, Via Monteroni, 73100 Lecce, Italy; (F.D.C.); (E.S.)
| | - Antonella Antonelli
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Via Saffi 2, 61029 Urbino, Italy; (P.A.); (F.L.); (M.G.N.); (M.M.)
| |
Collapse
|
2
|
Ninfali P, Antonelli A, Magnani M, Scarpa ES. Antiviral Properties of Flavonoids and Delivery Strategies. Nutrients 2020; 12:nu12092534. [PMID: 32825564 PMCID: PMC7551920 DOI: 10.3390/nu12092534] [Citation(s) in RCA: 66] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Revised: 08/14/2020] [Accepted: 08/18/2020] [Indexed: 12/18/2022] Open
Abstract
This review summarizes the latest advancements in phytochemicals as functional antiviral agents. We focused on flavonoids, like apigenin, vitexin, quercetin, rutin and naringenin, which have shown a wide range of biological effects including antiviral activities. The molecular mechanisms of their antiviral effects mainly consist in the inhibition of viral neuraminidase, proteases and DNA/RNA polymerases, as well as in the modification of various viral proteins. Mixtures of different flavonoids or combination of flavonoids with antiviral synthetic drugs provide an enhancement of their antiviral effects. Recent strategies in drug delivery significantly contribute to overcoming the low bioavailability of flavonoids. Frequent viral infections worldwide have led to the need for new effective antiviral agents, which can be identified among the various phytochemicals. In this light, screening the antiviral activities of a cocktail of flavonoids would be advantageous in order to prevent viral infections and improve current antiviral therapies.
Collapse
Affiliation(s)
| | | | - Mauro Magnani
- Correspondence: (M.M.); (E.S.S.); Tel.: +39-0722-305-211 (M.M.); +39-0722-305-252 (E.S.S.)
| | | |
Collapse
|
3
|
Ju Y, Guo H, Edman M, Hamm-Alvarez SF. Application of advances in endocytosis and membrane trafficking to drug delivery. Adv Drug Deliv Rev 2020; 157:118-141. [PMID: 32758615 PMCID: PMC7853512 DOI: 10.1016/j.addr.2020.07.026] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Revised: 07/28/2020] [Accepted: 07/29/2020] [Indexed: 12/12/2022]
Abstract
Multidisciplinary research efforts in the field of drug delivery have led to the development of a variety of drug delivery systems (DDS) designed for site-specific delivery of diagnostic and therapeutic agents. Since efficient uptake of drug carriers into target cells is central to effective drug delivery, a comprehensive understanding of the biological pathways for cellular internalization of DDS can facilitate the development of DDS capable of precise tissue targeting and enhanced therapeutic outcomes. Diverse methods have been applied to study the internalization mechanisms responsible for endocytotic uptake of extracellular materials, which are also the principal pathways exploited by many DDS. Chemical inhibitors remain the most commonly used method to explore endocytotic internalization mechanisms, although genetic methods are increasingly accessible and may constitute more specific approaches. This review highlights the molecular basis of internalization pathways most relevant to internalization of DDS, and the principal methods used to study each route. This review also showcases examples of DDS that are internalized by each route, and reviews the general effects of biophysical properties of DDS on the internalization efficiency. Finally, options for intracellular trafficking and targeting of internalized DDS are briefly reviewed, representing an additional opportunity for multi-level targeting to achieve further specificity and therapeutic efficacy.
Collapse
Affiliation(s)
- Yaping Ju
- Department of Pharmacology and Pharmaceutical Sciences, USC School of Pharmacy, USA
| | - Hao Guo
- Department of Pharmacology and Pharmaceutical Sciences, USC School of Pharmacy, USA
| | - Maria Edman
- Department of Ophthalmology, Roski Eye Institute, Keck School of Medicine, University of Southern California, USA
| | - Sarah F Hamm-Alvarez
- Department of Pharmacology and Pharmaceutical Sciences, USC School of Pharmacy, USA; Department of Ophthalmology, Roski Eye Institute, Keck School of Medicine, University of Southern California, USA.
| |
Collapse
|
4
|
Antonelli A, Szwargulski P, Scarpa ES, Thieben F, Cordula G, Ambrosi G, Guidi L, Ludewig P, Knopp T, Magnani M. Development of long circulating magnetic particle imaging tracers: use of novel magnetic nanoparticles and entrapment into human erythrocytes. Nanomedicine (Lond) 2020; 15:739-753. [PMID: 32207374 DOI: 10.2217/nnm-2019-0449] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Aim: Magnetic particle imaging (MPI) is highly promising for biomedical applications, but optimal tracers for MPI, namely superparamagnetic iron oxide-based contrast agents, are still lacking. Materials & methods: The encapsulation of commercially available nanoparticles, specifically synomag®-D and perimag®, into human red blood cells (RBCs) was performed by a hypotonic dialysis and isotonic resealing procedure. The amounts of superparamagnetic iron oxide incorporated into RBCs were determined by Fe quantification using nuclear magnetic resonance and magnetic particle spectroscopy. Results: Perimag-COOH nanoparticles were identified as the best nanomaterial for encapsulation in RBCs. Perimag-COOH-loaded RBCs proved to be viable cells showing a good magnetic particle spectroscopy performance, while the magnetic signal of synomag-D-COOH-loaded RBCs dropped sharply. Conclusion: Perimag-COOH-loaded RBCs could be a potential tool for MPI diagnostic applications.
Collapse
Affiliation(s)
- Antonella Antonelli
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Via Saffi 2, 61029, Urbino (PU), Italy
| | - Patryk Szwargulski
- Section for Biomedical Imaging, University Medical Center Hamburg-Eppendorf, Lottestr. 55, 22529, Hamburg, Germany.,Institute for Biomedical Imaging, Hamburg University of Technology, Am Schwarzenberg-Campus 3, 21073, Hamburg, Germany
| | - Emanuele-Salvatore Scarpa
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Via Saffi 2, 61029, Urbino (PU), Italy
| | - Florian Thieben
- Section for Biomedical Imaging, University Medical Center Hamburg-Eppendorf, Lottestr. 55, 22529, Hamburg, Germany.,Institute for Biomedical Imaging, Hamburg University of Technology, Am Schwarzenberg-Campus 3, 21073, Hamburg, Germany
| | - Grüttner Cordula
- Micromod Partikeltechnologie GmbH, Friedrich-Barnewitz-Str. 4 D-18119, Rostock, Germany
| | - Gianluca Ambrosi
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Via Saffi 2, 61029, Urbino (PU), Italy
| | - Loretta Guidi
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Via Saffi 2, 61029, Urbino (PU), Italy
| | - Peter Ludewig
- Department of Neurology, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany
| | - Tobias Knopp
- Section for Biomedical Imaging, University Medical Center Hamburg-Eppendorf, Lottestr. 55, 22529, Hamburg, Germany.,Institute for Biomedical Imaging, Hamburg University of Technology, Am Schwarzenberg-Campus 3, 21073, Hamburg, Germany
| | - Mauro Magnani
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, Via Saffi 2, 61029, Urbino (PU), Italy
| |
Collapse
|
5
|
Red blood cells as an efficient in vitro model for evaluating the efficacy of metallic nanoparticles. 3 Biotech 2019; 9:279. [PMID: 31245243 DOI: 10.1007/s13205-019-1807-4] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Accepted: 06/11/2019] [Indexed: 10/26/2022] Open
Abstract
Blood and the linings of blood vessels may be regarded as a fifth tissue type. The human body contains 5 × 109 red blood cells (RBCs) per ml, a total of 2.5 × 1013 cells in the 5 l of blood present in the body. With an average lifetime of 125 days, human RBCs are destroyed by leukocytes in the spleen and liver. Nowadays red blood cells are extensively used to study various metabolic functions. Nanoparticles (NP) are being widely accepted for drug delivery system. This review summarizes the red blood cells, NPs and their characteristics on the basis of the RBC components along with drug delivery systems through RBCs. Further, we also discussed that how erythrocytes can be used as an efficient in vitro model for evaluating the efficacy of various nanocomposite materials.
Collapse
|
6
|
Pan DC, Myerson JW, Brenner JS, Patel PN, Anselmo AC, Mitragotri S, Muzykantov V. Nanoparticle Properties Modulate Their Attachment and Effect on Carrier Red Blood Cells. Sci Rep 2018; 8:1615. [PMID: 29371620 PMCID: PMC5785499 DOI: 10.1038/s41598-018-19897-8] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Accepted: 01/04/2018] [Indexed: 01/01/2023] Open
Abstract
Attachment of nanoparticles (NPs) to the surface of carrier red blood cells (RBCs) profoundly alters their interactions with the host organism, decelerating NP clearance from the bloodstream while enabling NP transfer from the RBC surface to the vascular cells. These changes in pharmacokinetics of NPs imposed by carrier RBCs are favorable for many drug delivery purposes. On the other hand, understanding effects of NPs on the carrier RBCs is vital for successful translation of this novel drug delivery paradigm. Here, using two types of distinct nanoparticles (polystyrene (PSNP) and lysozyme-dextran nanogels (LDNG)) we assessed potential adverse and sensitizing effects of surface adsorption of NPs on mouse and human RBCs. At similar NP loadings (approx. 50 particles per RBC), adsorption of PSNPs, but not LDNGs, induces RBCs agglutination and sensitizes RBCs to damage by osmotic, mechanical and oxidative stress. PSNPs, but not LDNGs, increase RBC stiffening and surface exposure of phosphatidylserine, both known to accelerate RBC clearance in vivo. Therefore, NP properties and loading amounts have a profound impact on RBCs. Furthermore, LDNGs appear conducive to nanoparticle drug delivery using carrier RBCs.
Collapse
Affiliation(s)
- Daniel C Pan
- Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States
| | - Jacob W Myerson
- Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States
| | - Jacob S Brenner
- Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States
- Pulmonary and Critical Care Division, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States
| | - Priyal N Patel
- Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States
| | - Aaron C Anselmo
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States
| | - Samir Mitragotri
- School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, 02138, United States
| | - Vladimir Muzykantov
- Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States.
| |
Collapse
|
7
|
Bustamante López SC, Meissner KE. Characterization of carrier erythrocytes for biosensing applications. JOURNAL OF BIOMEDICAL OPTICS 2017; 22:91510. [PMID: 28384789 DOI: 10.1117/1.jbo.22.9.091510] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2016] [Accepted: 03/09/2017] [Indexed: 06/07/2023]
Abstract
Erythrocyte abundance, mobility, and carrying capacity make them attractive as a platform for blood analyte sensing as well as for drug delivery. Sensor-loaded erythrocytes, dubbed erythrosensors, could be reinfused into the bloodstream, excited noninvasively through the skin, and used to provide measurement of analyte levels in the bloodstream. Several techniques to load erythrocytes, thus creating carrier erythrocytes, exist. However, their cellular characteristics remain largely unstudied. Changes in cellular characteristics lead to removal from the bloodstream. We hypothesize that erythrosensors need to maintain native erythrocytes’ (NEs) characteristics to serve as a long-term sensing platform. Here, we investigate two loading techniques and the properties of the resulting erythrosensors. For loading, hypotonic dilution requires a hypotonic solution while electroporation relies on electrical pulses to perforate the erythrocyte membrane. We analyze the resulting erythrosensor signal, size, morphology, and hemoglobin content. Although the resulting erythrosensors exhibit morphological changes, their size was comparable with NEs. The hypotonic dilution technique was found to load erythrosensors much more efficiently than electroporation, and the sensors were loaded throughout the volume of the erythrosensors. Finally, both techniques resulted in significant loss of hemoglobin. This study points to the need for continued development of loading techniques that better preserve NE characteristics.
Collapse
Affiliation(s)
- Sandra C Bustamante López
- Texas A&M University, College of Engineering, Department of Biomedical Engineering, College Station, Texas, United States
| | - Kenith E Meissner
- Texas A&M University, College of Engineering, Department of Biomedical Engineering, College Station, Texas, United StatesbSwansea University, Department of Physics, Swansea, Wales, United Kingdom
| |
Collapse
|
8
|
Pan D, Vargas-Morales O, Zern B, Anselmo AC, Gupta V, Zakrewsky M, Mitragotri S, Muzykantov V. The Effect of Polymeric Nanoparticles on Biocompatibility of Carrier Red Blood Cells. PLoS One 2016; 11:e0152074. [PMID: 27003833 PMCID: PMC4803339 DOI: 10.1371/journal.pone.0152074] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Accepted: 03/08/2016] [Indexed: 11/22/2022] Open
Abstract
Red blood cells (RBCs) can be used for vascular delivery of encapsulated or surface-bound drugs and carriers. Coupling to RBC prolongs circulation of nanoparticles (NP, 200 nm spheres, a conventional model of polymeric drug delivery carrier) enabling their transfer to the pulmonary vasculature without provoking overt RBC elimination. However, little is known about more subtle and potentially harmful effects of drugs and drug carriers on RBCs. Here we devised high-throughput in vitro assays to determine the sensitivity of loaded RBCs to osmotic stress and other damaging insults that they may encounter in vivo (e.g. mechanical, oxidative and complement insults). Sensitivity of these tests is inversely proportional to RBC concentration in suspension and our results suggest that mouse RBCs are more sensitive to damaging factors than human RBCs. Loading RBCs by NP at 1:50 ratio did not affect RBCs, while 10–50 fold higher NP load accentuated RBC damage by mechanical, osmotic and oxidative stress. This extensive loading of RBC by NP also leads to RBCs agglutination in buffer; however, addition of albumin diminished this effect. These results provide a template for analyses of the effects of diverse cargoes loaded on carrier RBCs and indicate that: i) RBCs can tolerate carriage of NP at doses providing loading of millions of nanoparticles per microliter of blood; ii) tests using protein-free buffers and mouse RBCs may overestimate adversity that may be encountered in humans.
Collapse
Affiliation(s)
- Daniel Pan
- Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Omayra Vargas-Morales
- Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Blaine Zern
- Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Aaron C. Anselmo
- Department of Chemical Engineering and Center for Bioengineering, University of California Santa Barbara, Santa Barbara, California, United States of America
| | - Vivek Gupta
- Department of Chemical Engineering and Center for Bioengineering, University of California Santa Barbara, Santa Barbara, California, United States of America
| | - Michael Zakrewsky
- Department of Chemical Engineering and Center for Bioengineering, University of California Santa Barbara, Santa Barbara, California, United States of America
| | - Samir Mitragotri
- Department of Chemical Engineering and Center for Bioengineering, University of California Santa Barbara, Santa Barbara, California, United States of America
| | - Vladimir Muzykantov
- Department of Pharmacology and Center for Translational Targeted Therapeutics and Nanomedicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
- * E-mail:
| |
Collapse
|
9
|
Casagrande G, Arienti F, Mazzocchi A, Taverna F, Ravagnani F, Costantino M. Application of Controlled Shear Stresses on the Erythrocyte Membrane as a New Approach to Promote Molecule Encapsulation. Artif Organs 2016; 40:959-970. [DOI: 10.1111/aor.12662] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Giustina Casagrande
- Department of Chemistry, Materials and Chemical Engineering “Giulio Natta,”; Politecnico di Milano; Milan Italy
| | - Flavio Arienti
- Service of Immunohematology & Transfusion Medicine; Fondazione IRCCS Istituto Nazionale Tumori; Milan Italy
| | - Arabella Mazzocchi
- Service of Immunohematology & Transfusion Medicine; Fondazione IRCCS Istituto Nazionale Tumori; Milan Italy
| | - Francesca Taverna
- Service of Immunohematology & Transfusion Medicine; Fondazione IRCCS Istituto Nazionale Tumori; Milan Italy
| | - Fernando Ravagnani
- Service of Immunohematology & Transfusion Medicine; Fondazione IRCCS Istituto Nazionale Tumori; Milan Italy
| | - MariaLaura Costantino
- Department of Chemistry, Materials and Chemical Engineering “Giulio Natta,”; Politecnico di Milano; Milan Italy
| |
Collapse
|
10
|
Zhang J, Ma G, Lv Z, Zhou Y, Wen C, Wu Y, Xu R. Targeted thrombolysis strategies for neuroprotective effect. Neural Regen Res 2014; 9:1316-22. [PMID: 25221585 PMCID: PMC4160859 DOI: 10.4103/1673-5374.137580] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/12/2014] [Indexed: 12/24/2022] Open
Abstract
Stroke is usually treated by systemic thrombolytic therapy if the patient presents within an appropriate time window. There is also widespread interest in the development of thrombolytic agents that can be used in cases of delayed presentation. Current agents that can be used in cases of delayed presentation of nerve damage by thrombus. Current systemic thrombolytic therapy is associated with adverse effects such as fibrinogenolysis and bleeding. In an attempt to increase the efficacy, safety, and specificity of thrombolytic therapy, a number of targeted thrombolytic agents have been studied in recent years. This review focuses on the concepts underlying targeted thrombolytic therapy and describes recent drug developments in this field.
Collapse
Affiliation(s)
- Junping Zhang
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Guoxing Ma
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Zhimin Lv
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Yu Zhou
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Chunguang Wen
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Yaqing Wu
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Ruian Xu
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| |
Collapse
|
11
|
Zarrin A, Foroozesh M, Hamidi M. Carrier erythrocytes: recent advances, present status, current trends and future horizons. Expert Opin Drug Deliv 2014; 11:433-47. [PMID: 24456118 DOI: 10.1517/17425247.2014.880422] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Carrier erythrocytes, thanks to their main advantages, including biocompatibility, biodegradability, immunocompatibility, simple and well-known structure and physiology, availability for sampling and versatility in loading and use, have been studied as cellular carriers for delivery of drugs and other bioactive agents for more than three decades. Based on this body of knowledge and recent advances in this field, and with the help of novel multidisciplinary sciences and technologies, it seems that this field is becoming renowned and experiencing an outstanding turning point in its developmental history. AREAS COVERED In this trendy and timely review, following a short historical review of the story of erythrocytes from oxygen delivery to drug delivery and evaluation of the present status of these biocarriers, recent advances and current experimental, technological and clinical trends, as well as future horizons, and, in particular, translation-prone strategies, are going to be discussed in detail. EXPERT OPINION Despite the challenging developmental history of carrier erythrocytes, they now stand closer to clinical use and market entrance due to their unique advantages in drug delivery, proven by recently reported success stories in late-stage clinical trials and progresses made in biotechnology, nanotechnology and biomaterials fields. Translation-prone approaches, like in vivo loading of circulating erythrocytes or semiautomatic loading of erythrocytes, and more realistic study designs by focusing on clinical needs that have not been responded to or erythrocyte biology/fate-inspired study design are among the main trends being focused on by pioneer research groups active in this field of drug delivery.
Collapse
Affiliation(s)
- Abdolhossein Zarrin
- Shiraz University of Medical Sciences, Medicinal and Natural Products Chemistry Research Center , Shiraz , Iran
| | | | | |
Collapse
|
12
|
Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: In vivo performances. J Control Release 2012; 160:418-30. [DOI: 10.1016/j.jconrel.2012.03.013] [Citation(s) in RCA: 241] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2011] [Accepted: 03/08/2012] [Indexed: 01/08/2023]
|
13
|
Pierigè F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Deliv Rev 2008; 60:286-95. [PMID: 17997501 DOI: 10.1016/j.addr.2007.08.029] [Citation(s) in RCA: 189] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2007] [Accepted: 08/14/2007] [Indexed: 12/24/2022]
Abstract
Drug delivery has been greatly improved over the years by means of chemical and physical agents that increase bioavailability, improve pharmacokinetic and reduce toxicities. At the same time, cell based delivery systems have also been developed. These possesses a number of advantages including prolonged delivery times, targeting of drugs to specialized cell compartments and biocompatibility. Here we'll focus on erythrocyte-based drug delivery. These systems are especially efficient in releasing drugs in circulations for weeks, have a large capacity, can be easily processed and could accommodate traditional and biologic drugs. These carriers have also been used for delivering antigens and/or contrasting agents. Carrier erythrocytes have been evaluated in thousands of drug administration in humans proving safety and efficacy of the treatments. Erythrocyte-based delivery of new and conventional drugs is thus experiencing increasing interests in drug delivery and in managing complex pathologies especially when side effects could become serious issues.
Collapse
Affiliation(s)
- F Pierigè
- Institute of Biological Chemistry Giorgio Fornaini, University of Urbino Carlo Bo, Urbino, Italy
| | | | | | | |
Collapse
|
14
|
Rossi L, Serafini S, Pierigé F, Antonelli A, Cerasi A, Fraternale A, Chiarantini L, Magnani M. Erythrocyte-based drug delivery. Expert Opin Drug Deliv 2006; 2:311-22. [PMID: 16296756 DOI: 10.1517/17425247.2.2.311] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The use of a physiological carrier to deliver therapeutics throughout the body to both improve their efficacy while minimising inevitable adverse side effects, is an extremely fascinating perspective. The behaviour of erythrocytes as a delivery system for several classes of molecules (i.e., proteins, including enzymes and peptides, therapeutic agents in the form of nucleotide analogues, glucocorticoid analogues) has been studied extensively as they possess several properties, which make them unique and useful carriers. Furthermore, the possibility of using carrier erythrocytes for selective drug targeting to differentiated macrophages increases the opportunities to treat intracellular pathogens and to develop new drugs. Finally, the availability of an apparatus that permits the encapsulation of drugs into autologous erythrocytes has made this technology available in many clinical settings and competitive with other drug delivery systems.
Collapse
Affiliation(s)
- Luiga Rossi
- Università degli Studi di Urbino Carlo Bo, Istituto di Chimica Biologica G Fornaini, Italy
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Chiarantini L, Cerasi A, Fraternale A, Millo E, Benatti U, Sparnacci K, Laus M, Ballestri M, Tondelli L. Comparison of novel delivery systems for antisense peptide nucleic acids. J Control Release 2005; 109:24-36. [PMID: 16290244 DOI: 10.1016/j.jconrel.2005.09.013] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2005] [Accepted: 08/15/2005] [Indexed: 11/17/2022]
Abstract
Peptide nucleic acids (PNAs) provide a powerful tool to study the mechanism of transcription and translation, an innovative strategy to regulate target gene expression. They have been successfully used in antisense technology, for their ability to specifically bind to messenger RNA (mRNA) targets and to inhibit translation of the target genes. However, unlike most of the DNA and RNA oligonucleotides, PNAs are poorly penetrated through the cell membrane, partially due to their uncharged property. To enhance the efficiency in PNA delivery, many strategies have been explored. We here compare the efficacy of three different delivery strategies for antisense PNA: 1) conjugation to hydrophobic peptides, 2) adsorption onto polymeric microspheres and 3) encapsulation in autologous erythrocytes. To this purpose, we designed and prepared PNA sequences able to inhibit the expression of macrophage enzymes involved in inflammatory process, i.e. nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) and tested their antisense activity in a murine macrophage cellular model. Both delivery through polymeric microspheres and encapsulation into erythrocytes allowed the antisense activity of unmodified PNAs at nanomolar concentration.
Collapse
Affiliation(s)
- Laura Chiarantini
- Institute of Biochemistry Giorgio Fornaini, University of Urbino Carlo Bo, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Rossi L, Serafini S, Antonelli A, Pierigé F, Carnevali A, Battistelli V, Malatesta M, Balestra E, Caliò R, Perno CF, Magnani M. Macrophage depletion induced by clodronate-loaded erythrocytes. J Drug Target 2005; 13:99-111. [PMID: 15823961 DOI: 10.1080/10611860500064123] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Given the important role of macrophages in various disorders, the transient and organ specific suppression of their functions may benefit some patients. Until now, liposome-encapsulated bisphosphonate clodronate has been extensively proposed to this end. In this paper, we demonstrate that erythrocytes loaded with clodronate can also be effective in macrophage depletion. Here, clodronate was encapsulated in erythrocytes through hypotonic dialysis, isotonic resealing and reannealing to final concentrations of 4.1 +/- 0.4 and 10.1 +/- 0.8 micromol/ml of human and murine erythrocytes, respectively. The ability of clodronate-loaded erythrocytes to deplete macrophages was evaluated both in vitro and in vivo. In vitro studies on human macrophages showed that a single administration of engineered erythrocytes was able to reduce cell adherence capacity in a time-dependent manner, reaching 50 +/- 4% reduction, 13 days post treatment. The administration of loaded erythrocytes to cultures of murine peritoneal macrophages was able to reduce macrophage adhesion 67 +/- 3%, 48 h post treatment. In vivo, the ability of clodronate-loaded erythrocytes to deplete macrophages was evaluated both in Swiss and C57BL/6 mice. Swiss mice received 125 microg of clodronate through erythrocytes and 6 days post treatment 69 +/- 7% reduction in the number of adherent peritoneal macrophages and 75 +/- 5% reduction in number of spleen macrophages were observed. C57BL/6 mice received 220 microg clodronate by RBC and 3 and 8 days post treatment 65 +/- 7% reduction in the number of spleen macrophages and the complete depletion of liver macrophages were obtained. In summary, our results indicate that clodronate selectively targeted to the phagocytic cells by a single administration of engineered erythrocytes is able to deplete macrophages, even if not completely. The transient suppression of macrophage functions through clodronate-loaded erythrocytes can be used in many biomedical phenomena and research applications.
Collapse
Affiliation(s)
- Luigia Rossi
- Institute of Biochemistry G. Fornaini, University of Urbino, 61029 Urbino (PU), Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|